206650 — EuBiologics Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩507bn
- KR₩505bn
- KR₩69bn
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 33,073 | 28,490 | 39,385 | 55,467 | 69,366 |
Cost of Revenue | |||||
Gross Profit | 19,909 | 6,927 | 15,261 | 23,613 | 34,019 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 23,263 | 31,411 | 47,323 | 60,080 | 83,573 |
Operating Profit | 9,809 | -2,921 | -7,938 | -4,614 | -14,207 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -628 | -60,595 | -30,820 | -3,338 | -14,615 |
Provision for Income Taxes | |||||
Net Income After Taxes | -882 | -60,134 | -28,025 | -3,437 | -15,360 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -882 | -60,134 | -27,574 | -1,099 | -13,879 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -882 | -60,134 | -27,574 | -1,099 | -13,879 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -32.6 | -2,161 | -765 | -18.5 | -19.8 |
Dividends per Share |